Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors

F1000Research

Volumn 2, Issue , 2013, Pages

  Tomasetti, Cristian ^a,b,c,d   Demetri, George D ^b   Parmigiani, Giovanni ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NEW DRUG; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MATHEMATICAL ANALYSIS; TREATMENT OUTCOME;

EID: 84904764055     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.2-152.v1     Document Type: Article

References (19)

1. Corless CL Heinrich MC: Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-86. 18039140 10.1146/annurev.pathmechdis.3.121806.151538
2. Le Cesne A Ray-Coquard I Bui BN: Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942-9. 20864406 10.1016/S1470-2045(10)70222-9
3. Antonescu CR Besmer P Guo T: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11(11):4182-90. 15930355 10.1158/1078-0432.CCR-04-2245
4. Antonescu CR: The GIST paradigm: lessons for other kinase-driven cancers. J Pathol. 2011;223(2):251-61. 21125679 10.1002/path.2798
5. Hochhaus A O'Brien SG Guilhot F: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-61. 19282833 10.1038/leu.2009.38
6. Tomasetti C Levy D: Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci U S A. 2010;107(39):16766-71. 20826440 10.1073/pnas.1007726107 2947914
7. Diaz LA Jr Williams RT Wu J: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012;486(7404):537-40. 22722843 10.1038/nature11219 3436069
8. Araten DJ Golde DW Zhang RH: A quantitative measurement of the human somatic mutation rate. Cancer Res. 2005;65(18):8111-7. 16166284 10.1158/0008-5472.CAN-04-1198
9. Drake JW Charlesworth B Charlesworth D: Rates of spontaneous mutation. Genetics. 1998;148(4):1667-86. 9560386 1460098
10. Heinrich MC Corless CL Blanke CD: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764-74. 16954519 10.1200/JCO.2006.06.2265
11. Wang WL Conley A Reynoso D: Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011;67(Suppl 1):S15-24. 21181476 10.1007/s00280-010-1513-8
12. Klein M Bartoszynski R: Estimation of growth and metastatic rates of primary breast cancer. In Mathematical Population Dynamics. (eds. Arino, O., Axelrod, D.E. & Kimmel, M.) (Marcel Dekker, New York, 1991).
13. Tomasetti C: A new hypothesis: imatinib affects leukemic stem cells in the same way it affects all other leukemic cells. Blood Cancer J. 2011;1(5):e19. 22829154 10.1038/bcj.2011.17 3255261
14. Rossi F Ehlers I Agosti V: Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci U S A. 2006;103(34):12843-8. 16908864 10.1073/pnas.0511076103 1568935
15. Bardsley MR Horváth VJ Asuzu DT: Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology. 2010;139(3):942-52. 20621681 10.1053/j.gastro.2010.05.083 2933938
16. Lorincz A Redelman D Horváth VJ: Progenitors of interstitial cells of cajal in the postnatal murine stomach. Gastroenterology. 2008;134(4):1083-93. 18395089 10.1053/j.gastro.2008.01.036 2435491
17. R_Core_Team. R: A Language and Environment for Statistical Computing. 2.15.3 edn (R Foundation for Statistical Computing, Vienna, Austria, 2013). Reference Source
18. Blanke CD Demetri GD von Mehren M: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-5. 18235121 10.1200/JCO.2007.13.4403
19. Demetri GD van Oosterom AT Garrett CR: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38. 17046465 10.1016/S0140-6736(06)69446-4